BRUFEN ANALGESIC TABS COATED WITH FILM
Non-steroidal anti-inflammatory and anti-rheumatic products, propionic acid derivatives.
Each tablet contains 200 mg of ibuprofen (as lysine salt). Each tablet contains 400 mg of ibuprofen (as lysine salt).
Tablet core: microcrystalline cellulose (E460), anhydrous colloidal silica (E551), crospovidone (E1202), povidone (E1201), magnesiostearate (E572), talc (E553b). Tablet coating: polyvinyl alcohol hydrolyzed (E1203), titanium dioxide (E171), macrogol (E1521), talc (E553b). Printing ink: shellac (E904), black iron oxide (E172), ammonium hydroxide (E527).
(Only 200 mg). For the symptomatic treatment of mild to moderate pain such as headache, dental pain, menstrual pain and fever and pain in the common cold. (400 mg only). For the symptomatic treatment of mild to moderate pain such as headache, acute cone migraine without aura, dental pain, menstrual pain and fever and pain in the common cold.
CONTRAINDICATIONS / EFF.SECONDAR
Ibuprofen is contraindicated in patients: with hypersensitivity to active substance or to any of the excipients, with previous hypersensitivity reactions (e.g. bronchospasm, angioedema, rhinitis, urticaria or asthma) in response to acetylsalicylic acid (ASA) or to other nonsteroidal anti-inflammatory drugs (NSAIDs), with the presence or history of peptic ulcer / recurrent bleeding (two or more distinct episodes of demonstrated ulceration or bleeding), with a history of gastrointestinal bleeding or perforation related to previous NSAID treatments, with severe insufficiency hepatic, severe renal failure or severe heart failure (NYHA Class IV), (Only 200 mg) children under 20 kg of weight (about 6 years of age); (Only 400 mg) adolescents under 40 kg of weight or children under 12 years of age; with cerebrovascular hemorrhage or other types of active hemorrhage, unexplained blood formation disorders, with severe dehydration (caused by vomiting, diarrhea or insufficient fluid intake), during the last trimester of pregnancy.
Adults and adolescents> = 40 kg of body weight (12 years of age and over). (200 mg only) Starting dose: 200 mg or 400 mg. If necessary, an additional dose of 1 or 2 tablets (200 mg to 400mg) can be taken. The corresponding dose interval should be chosen based on the symptoms and the maximum recommended daily dose. It should not be less than 6 hours for a 400 mg dose and not less than 4 hours for a 200 mg dose. Do not exceed the 1200 mg dose in any 24 hour period. (400 mg only) Starting dose: 400 mg. If necessary, an additional dose of 400 mg can be taken. The corresponding dose interval should be chosen based on the symptoms and the maximum recommended daily dose. It should not be less than 6 hours for a 400 mg dose. Do not exceed the 1200 mg dose in any 24 hour period. For the treatment of migraine, the dose should be one 400 mg tablet as a single dose, 400 mg if necessary in 4 to 6 hour intervals. Do not exceed the 1200 mg dose in any 24 hour period. Pediatric population (200 mg only). Children over 6 years (20 kg - 40 kg of body weight). Ibuprofen should only be used in children with a body weight of at least 20 kg. The maximum daily dose of ibuprofen is 20 - 30 mg of ibuprofen per kg bodyweight, divided into 3 or 4 individual doses with a transient interval of 6 to 8 hours. The maximum recommended daily dose should not be exceeded. A maximum dosage of 30 mg / kg of ibuprofen in a 24 hour period should not be exceeded. The following dosage information applies. Body weight: 20 kg - 29 kg; single dose: 1 tablet (200 mg ibuprofen); maximum daily dose: 3 tablets (equivalent to 600 mg ibuprofen). Body weight: 30 kg- 39 kg; single dose: 1 tablet (200 mg ibuprofen); maximum daily dose: 4 tablets (equivalent to 800 mg of ibuprofen). In the event that this medicine is required for more than 3 days in children over the age of 6 years and in adolescents or in case the symptoms worsen it is necessary to seek medical attention. Children under 6 years old. The medicine is contraindicated in children under 6 years. (400 mg only) The drug is contraindicated in adolescents under 40 kg of body weight or in children under 12 years of age. In the event that this medicine is required for more than 3 days in children over the age of 12 years and in adolescents or in case the symptoms worsen it is necessary to seek medical attention. Side effects can be minimized with the use of the lowest effective dose for the shortest possible duration of treatment needed to control symptoms. For short-term use only. If the medicine is required for more than 3 days in headache or fever chaos for more than 4 days for the treatment of pain or if symptoms worsen, the patient should be advised to consult a doctor. Elderly patients No dose adjustment is necessary. Elderly patients should be monitored especially carefully because of the possible side effect profile. Patients with gastric sensitivity Patients with a sensitive stomach must take the medicine during a meal. Taking ibuprofen after a meal can delay the onset of its action. If this happens, additional ibuprofen should not be taken until the corresponding dose interval has elapsed. Patients with renal impairment. No dose reduction is required in patients with mild to moderate renal impairment. Patients with hepatic impairment. No dose reduction is required in patients with mild to moderate hepatic impairment. Method of administration For oral administration and short-term use only. Ibuprofen tablets should be swallowed whole with plenty of water. Do not chew the tablets.
This medicine does not require special storage conditions.
Undesirable effects can be minimized by using the lowest effective dose for the shortest time necessary to achieve symptom control (see effects on the gastrointestinal and cardiovascular systems). Caution should be exercised when administering ibuprofen in patients suffering from the following conditions, which may worsen: congenital disturbances of porphyrin metabolism (e.g. intermittent acute porphyria), coagulation disorders (ibuprofen may prolong the duration of coagulation ), directly after major surgery, systemic lupus erythematosus and mixed connective tissue disease (e.g. increased risk of meningitiseaseptic), hypertension and / or heart failure, as renal function may deteriorate, in patients suffering from hay fever, nasal polyps or chronic obstructive respiratory disorders, since there is an increased risk of allergic reactions for them . These can present an attack of asthma (so called asthma by analgesics), Quincke's edema or urticaria, in patients who react with allergy to other substances, since there is also an increased risk of the appearance of hypersensitivity reactions during use of ibuprofen. Senior citizens. The elderly have an increased frequency of adverse reactions to NSAIDs, especially gastrointestinal bleeding and perforation, which can be fatal. Respiratory reactions A bronchospasm can be precipitated in patients suffering from bronchial asthma or allergic diseases or with a history of these diseases. Other NSAIDs. The use of ibuprofen with other NSAIDs, including selective cyclooxygenase-2 inhibitors, increases the risk of adverse reactions and should be avoided. Kidney effects. Renal impairment, as renal function may deteriorate further. In general terms, the usual intake of analgesics, in particular the association of different analgesic substances, can lead to permanent kidney damage with the risk of kidney failure (analgesic nephropathy). This risk may increase under physical exertion associated with loss of salts and dehydration. Therefore it must be avoided. There is a risk of renal impairment in dehydrated children and adolescents. Liver effects. Liver dysfunction. It is appropriate to discontinue ibuprofen therapy when deterioration of liver function occurs concurrently with its administration. After stopping treatment, your health usually normalizes. Occasional blood glucose monitoring is also appropriate. Cardiovascular and cerebrovascular effects. Particular caution is required (discuss with your doctor or pharmacist) before starting treatment in patients with a history of hypertension and / or heart failure, because water retention, hypertension and edema have been reported in association with NSAID therapy. Patients suffering from uncontrolled hypertension (NYHA class II-III), congestive heart failure, known ischemic heart disease, arterial peripheral disease and / or cerebrovascular disease should only be treated with ibuprofen after careful consideration and high doses should be avoided. (2400 mg / day). Careful consideration should also be exercised before starting long-term treatment in patients with risk factors for cardiovascular events (e.g. hypertension, hyperlipidaemia, diabetes mellitus or smoking), particularly if high doses of ibuprofen (2400 mg / day) are needed. Clinical studies suggest that the use of ibuprofen, especially at a high dose (2400 mg / day) and for long-term treatments, may be associated with a slight increase in the risk of arterial thrombotic events (e.g. myocardial infarction or stroke). In general, epidemiological studies do not indicate that low doses of ibuprofen (e.g. <= 1200 mg / day) are associated with an increased risk of arterial thrombotic events. Alteration of female fertility. There is some evidence that pharmaceuticals inhibit the synthesis of cyclooxygenases / prostaglandins, they can cause alterations in female fertility, through an effect on ovulation. This is reversible after stopping treatment. Gastrointestinal safety. NSAIDs should be administered with caution to patients with a history of gastrointestinal disease (ulcerative colitis, Crohn's disease), as these conditions can be exacerbated. Gastrointestinal haemorrhage, ulceration or perforation, which can be fatal, has been reported during treatment with all NSAIDs, at any time during therapy, with or without warning symptoms or a previous history of serious gastrointestinal events. In patients with a history of ulcer, especially if complicated by bleeding or perforation, and in the elderly, the risk of gastrointestinal bleeding, ulceration or perforation is greater with increasing NSAID doses. These patients should start treatment with the lowest available dose. It is appropriate to consider the concomitant use of protective agents (e.g. misoprostol or proton pump inhibitors) both for these patients and for patients taking concomitant low doses of acetylsalicylic acid or other drugs that may increase the risk of gastrointestinal events. Patients with a history of gastrointestinal toxicity, in particular Seanzians, must report any symptoms of an unusual gastrointestinal nature (especially gastrointestinal bleeding) in particular in the initial stages of treatment. Caution is needed in the treatment of patients taking concomitant medications that could increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors or antiplatelet agents such as acetylsalicylic acid. When bleeding occurs or gastrointestinal ulceration in patients taking ibuprofen, treatment should be stopped. Skin reactions Serious skin reactions, some of them fatal, such as exfoliative dermatitis, Steven-Johnson syndrome and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs. In the early stages of therapy, patients seem to be at a higher risk of these reactions: in fact, the onset of the reaction occurs in most cases within the first month of treatment. The use of ibuprofen must be discontinued at the first appearance of a skin rash, mucosal lesion or any other sign of hypersensitivity. Exceptionally chickenpox can cause serious skin reactions and infectious complications to soft tissues.
The use of ibuprofen should be avoided in combination with acetylsalicylic acid. Concomitant administration of ibuprofen and acetylsalicylic acid is generally not recommended due to the potential increase in side effects. Experimental data suggest that ibuprofen can competitively inhibit the effect of low-dose acetylsalicylic acid on platelet aggregation when the two drugs are administered simultaneously. Although there are uncertainties regarding the extrapolation of these data from the clinical situation, the possibility that regular, long-term use of ibuprofen may reduce the cardioprotective effect of low-dose acetylsalicylic acid cannot be excluded. No relevant clinical effects are considered likely following occasional use of ibuprofen. Other NSAIDs including salicylates and selective cyclooxygenase-2 inhibitors: avoid the concomitant use of two or more NSAIDs, because it may increase the risk of gastrointestinal ulcers and bleeding due to a synergistic effect. Anticoagulants: NSAIDs can increase the effects of anticoagulants, such as warfarin. Diuretics, ACE inhibitors and angiotensin II antagonists: NSAIDs can reduce the effect of diuretics and other antihypertensive drugs. In some patients with impaired kidney function (e.g. dehydrated patients or elderly patients with impaired renal function) the co-administration of an ACE inhibitor or an angiotensin II antagonist and agents that inhibit the cyclooxygenase system may result in further deterioration of renal function, including renal failure acute, which is generally reversible. Therefore, the combination should be administered with caution, especially in elderly patients. Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant therapy and regularly thereafter. Potassium-sparing diuretics: concomitant administration of ibuprofen and potassium-sparing diuretics, can lead to hyperkalaemia (control of serum potassium is recommended). Corticosteroids: increased risk of adverse reactions, especially of the gastrointestinal tract (gastrointestinal ulceration or bleeding). Antiplatelet agents and selective serotonin reuptake inhibitors (SSRIs): increased risk of gastrointestinal bleeding. Digoxin: NSAIDs can exacerbate heart failure, reduce the rate of glomerular filtration and increase plasma digoxin levels. A check of serum digoxin is not required, as a rule, in the correct use (maximum 4 days). Phenytoin: concomitant use of ibuprofen with phenytoin preparations may increase serum phenytoin levels. A check of serum phenytoin is not required, as a rule, in the correct use (maximum 4 days). Lithium: there is evidence of potential increases in plasma lithium levels. A serum lithium check is not required, as a rule, in the correct use (maximum 4 days). Methotrexate: administration of ibuprofen within 24 hours before the administration of methotrexate may lead to an increase in the concentration of methotrexate and an increase in toxic effects. Cyclosporine: the risk of a harmful effect on the kidneys due to cyclosporine is increased by the co-administration of some NSAIDs. This effect cannot be excluded also for the association of cyclosporine with ibuprofen. Mifepristone. NSAIDs should not be used for 8-12 days after administration of mifepristone, because NSAIDs can reduce the effect of mifepristone. Sulfinpyrazone: medicines containing sulfinpyrazone may delay the excretion of ibuprofen.Probenecid: medicines containing probenecid may decrease the excretion of NSAIDs and may increase their serum concentrations. Tacrolimus: possible increased risk of nephrotoxicity if NSAIDs are co-administered with tacrolimus. Zidovudine: increased risk of haematological toxicity when NSAIDs are co-administered with zidovudine. A blood cell count is recommended 1-2 weeks after the start of co-administration. There are indications of an increased risk of hemarthrosis and hematoma in HIV positive patients with hemophilia being treated concomitantly with zidovudine and ibuprofen. Sulphonylureas: NSAIDs can both increase and decrease the hypoglycaemic effect of sulphonylureas. Caution is advised in case of simultaneous treatment. Quinolone antibiotics: animal data indicate that NSAIDs may increase the risk of seizures associated with quinolone antibiotics. Patients taking NSAIDs and quinolones may have an increased risk of developing seizures. Alcohol, bisphosphonates, oxpentifylline (pentoxifylline) and sulfinpyrazone: they can enhance gastrointestinal effects and the risk of bleeding or ulceration. Baclofen: increased delbaclofene toxicity.
The possible side effects are those observed with acid ibuprofen. The side effects are mostly dose dependent and vary individually. In particular, the risk of gastrointestinal bleeding is dependent on the dose and duration of treatment. The following side effects are related to the short-term use of low-dose ibuprofen (up to 1200 mg per day for mild to moderate pain and fever). Other undesirable effects may occur with treatments for other indications or prolonged use. The side effects associated with ibuprofen are listed in the table below according to system organ class and frequency. Frequencies are defined as very common (> = 1/10), common (> = 1/100 and <1/10), uncommon (> = 1/1000 and <1/100), rare (> = 1 / 10.000 and <1/1000), very rare (<1 / 10.000) and not known (cannot be defined on the basis of available data). For each frequency, the undesirable effects are listed in descending order of frequency. Blood and lymphatic system disorders. Very rare: hematopoietic pathologies. Immune system disorders. Uncommon: hypersensitivity reactions with urticaria and pruritus; very rare: severe hypersensitivity reactions. Symptoms may include: swelling of the face, tongue and larynx, edema, dyspnoea, tachycardia, hypotension (anaphylaxis, angioedema or severe shock). Psychiatric disorders. Rare: confusion, hallucinations; not known: psychotic disorders, depression. Nervous system disorders. Common: headache, drowsiness, dizziness, fatigue, agitation, dizziness, insomnia, irritability; very rare: aseptic meningitis. Eye disorders. Not known: amblyopia, blurred vision, reduced vision. Ear and labyrinth disorders. Rare: tinnitus. Cardiac pathologies. Very rare: palpitations, myocardial infarction, acute pulmonary edema; not known: heart failure, edema. Vascular pathologies. Not known: arterial hypertension. Respiratory, thoracic and mediastinal disorders. Uncommon: rhinitis; very rare: exacerbation of asthma; not known: respiratory tract reactions such as bronchospasm, asthma or dyspnoea. Gastrointestinal pathologies. Very common: heartburn, abdominal pain, nausea, dyspepsia, diarrhea, flatulence, constipation and vomiting; common: peptic ulcer, gastrointestinal perforation or bleeding, melena, hematemesis, ulcerative stomatitis, colitis; uncommon: gastritis; very rare: esophagitis, pancreatitis, intestinal narrowing; note: exacerbation of colitis and crohn's disease. Hepatobiliary pathologies. Very rare: liver dysfunction, liver damage, especially in long-term use, liver failure, acute hepatitis and jaundice. Skin and subcutaneous tissue disorders. Uncommon: photosensitivity, rash; very rare: severe forms of soft tissue skin reactions can occur during chickenpox infections, necrotizing fasciitis, exfoliative dermatitis, bullous reactions, including steven-johnson syndrome, erythema multiforme and toxic epidermal necrolysis; not known: alopecia, adverse reaction with eosinophilia and systemic symptoms (dress syndrome); kidney and urinary pathologies. Uncommon: development of edema, especially in patients with arterial hypertension or renal failure, nephrotic syndrome, interstitial nephritis which may be associated with renal failure; rare: renal papillary necrosis; very rare: acute renal failure, dysuria. Reproductive system and breast disorders. Not known: menstrual disorders. Diagnostic tests. Rare: increase in urea nitrogen, transaminases and alkaline phosphatase, decrease in hemoglobin and hematocrit values, inhibition of platelet aggregation, decrease in serum calcium, increase in serum uric acid; not known: prolonged bleeding time. Reporting of suspected adverse reactions Reporting of suspected adverse reactions which occur after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit / risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at http://www.agenziafarmaco.gov.it/content/come-segnalare-una-sosp etta-reaction-adverse.
PREGNANCY AND BREASTFEEDING
Pregnancy. Inhibition of prostaglandin synthesis can negatively affect pregnancy and / or embryo / fetal development. The data from epidemiological studies show an increased risk of abortion and cardiac malformation and gastroschisis after the use of an inhibitor of prostaglandin synthesis in the early stages of pregnancy. The risk is believed to increase with dose and duration of therapy. In animals, the administration of prostaglandin synthesis inhibitors induced an increase in pre- and post-implantation loss and embryo-fetal mortality. In addition, an increase in the incidence of various malformations, including cardiovascular malformation, has been reported in animals given prostaglandin synthesis inhibitors during the period of organogenesis. During the first and second trimester of pregnancy, ibuprofen should not be administered, except in strictly necessary cases. Whichever ibuprofen is used by a woman awaiting conception during the first and second trimester of pregnancy, the dose and duration of treatment should be kept as low as possible. During the third trimester of pregnancy, all synthesis inhibitors prostaglandins may expose the fetus to: cardiopulmonary toxicity (with premature closure of the arterial duct and pulmonary hypertension); kidney dysfunction, which can progress to kidney failure with oligo idramnios; the mother and the newborn, at the end of the pregnancy, to: possible prolongation of the bleeding time and antiplatelet effect which can also occur at very low doses; inhibition of uterine contractions with consequent delay or prolonged labor. Consequently, the use of ibuprofen is contraindicated during the third trimester of pregnancy. Feeding time. Only small quantities of ibuprofen and its metabolism products are excreted in breast milk. To date, no harmful effects are known in the infant. Consequently, ibuprofen can be used during breastfeeding for the treatment of short-term pain and fever and at the recommended doses. Long-term safety has not been established. Fertility'. There is evidence showing that drugs that inhibit cyclooxygenase / prostaglandin synthesis can cause impairment of female fertility following an effect on ovulation. This event is however reversible with the suspension of treatment. ]]>
Delivery is made within 24-72 working hours, Monday to Friday, excluding holidays.
WARNING! In times of high turnout, such as Black Friday, Christmas or Sales, delivery times may increase.
Shipping costs are calculated automatically during the order phase.
- EXPRESS shipping 24-72 working hours
For orders over € 40,00 shipping is free. For orders less than € 40,00 the following applies:
- - € 0,00 - € 9,99: € 6,99
- - € 10,00 - € 19,99: € 5,99
- - € 20,00 - € 29,99: € 4,99
- - € 30,00 - € 39,99: € 3,99
- - € 40,00 and up: € 0,00
- Cash on delivery
For orders over € 70,00 shipping is € 3.99. For orders less than € 70,00 the following applies:
- - € 0,00 - € 9,99: € 10,98
- - € 10,00 - € 19,99: € 9,98
- - € 20,00 - € 29,99: € 8,98
- - € 30,00 - € 39,99: € 7,98
- - € 40,00 - € 49,99: € 6,98
- - € 50,00 - € 59,99: € 5,98
- - € 60,00 - € 69,99: € 4,98
- - € 70,00 and up: € 3,99
WARNING! If you want to pay cash on delivery, when ordering you need to select the item twice, otherwise the total amount will be added € 3,99 for the service.
- Delivery by 12.00 TNT Express
By placing the order by 12:30 on the current day, delivery will take place by 12.00 on the following day, excluding Saturday and Sunday.
- € 10.99
- Delivery by 10.00 TNT Express
By placing the order by 12:30 on the current day, delivery will take place by 10.00 on the following day, excluding Saturday and Sunday.
- € 15.99
- € 7.98
Farmaveloce will deliver your order to the address of your choice throughout Italy, including the islands.
All orders with EXPRESS Shipping are entrusted to the Courier BRT, GLS, UPS, DHL, FedEx & TNT, Poste Italiane.
farmaveloce.com collects some Personal Data from its Users.
Owner of the Data Privacy
Via Savelli, 10 35129 Padua (Italy)
Email address of the owner: ROAD@ farmaveloce.com
The site: farmaveloce.com
Types of data collected
Among the Personal Data collected, independently or through third parties, there are: Cookies, Data of
use, name, surname, telephone number, VAT number, address, country, postcode, various types
of data, city and tax code.
Full details on each type of data collected are provided in the dedicated sections of this
Personal Data can be freely provided by the User or, in the case of Usage Data,
collected automatically when using the site.
Unless otherwise specified, all data requested by the site are mandatory.
If the User refuses to communicate them, it may be impossible for farmaveloce.com to provide the Service.
In cases where farmaveloce.com indicates some Data as optional, Users are free to
refrain from communicating such Data, without this having any consequence on the availability of the
Service or its operation.
Users who have doubts about which data are mandatory are encouraged to contact
of third party services used by the site, unless otherwise specified, has the purpose of providing the Service
requested by the User, in addition to the additional purposes described in this document and in the Cookie
Policy, if available.
The User assumes responsibility for the Personal Data of third parties obtained, published or shared
through farmaveloce.com and guarantees to have the right to communicate or disseminate them, freeing
the Owner from any liability to third parties.
Mode and place of processing of data collected
Mode of treatment
The Data Controller adopts the appropriate security measures to prevent access, disclosure, the
unauthorized modification or destruction of Personal Data.
The treatment is carried out using IT and / or telematic tools, with methods
organizational and with logic strictly related to the purposes indicated. In addition to the owner, in some
cases, other subjects involved in the organization of the site (staff
administrative, commercial, marketing, legal, system administrators) or external subjects
(such as third party technical service providers, couriers, hosting providers, IT companies,
communication agencies) also appointed, if necessary, Data Processors by the
Holder. The updated list of Managers can always be requested from the Data Controller
Legal basis of the processing
The Holder processes Personal Data relating to the User in the event one of the following conditions exists:
• the User has given consent for one or more specific purposes; Note: in some systems
the Data Controller can be authorized to process Personal Data without the existence of the
User's consent or another of the legal bases specified below, until
the User does not object ("opt-out") to this treatment. This however is not applicable if
the processing of Personal Data is regulated by European legislation on
protection of personal data;
• processing is necessary for the execution of a contract with the User and / or for the execution of
• processing is necessary to fulfill a legal obligation to which the Data Controller is subject;
• processing is necessary for the performance of a public interest task or for
the exercise of public powers with which the Data Controller is invested;
• the processing is necessary for the pursuit of the legitimate interest of the owner or third parties.
In any case, it is always possible to request the Data Controller to clarify the concrete legal basis of each
treatment and in particular to specify whether the treatment is based on the law, provided for by a
contract or necessary to conclude a contract.
The data are processed at the owner's operating offices and in any other place where the parties involved
in the treatment are localized.
For more information, contact the owner.
The User's Personal Data may be transferred to a country other than the one in which the User
is situated. To obtain further information on the place of treatment, the User can refer to
to the section on details on the processing of Personal Data.
The User has the right to obtain information regarding the legal basis for the transfer of Data to
outside the European Union or to an international international law organization
public or consisting of two or more countries, such as the UN, as well as on the measures of
security adopted by the Data Controller to protect the Data.
The User can check whether one of the transfers described above takes place by examining the section
of this document relating to details on the processing of Personal Data or request information from the
Owner by contacting him at the ends shown at the beginning.
The Data are processed and stored for the time required by the purposes for which they were collected.
• Personal Data collected for purposes related to the execution of a contract between the Owner and
the User will be held until the execution of this contract is completed.
• Personal Data collected for purposes related to the legitimate interest of the Owner will be
held until the satisfaction of this interest. The User can get further
information on the legitimate interest pursued by the Data Controller in the relevant sections of
this document or by contacting the owner.
When the treatment is based on the User's consent, the Data Controller can keep Personal Data
longer until such consent is revoked. In addition, the owner could be
obliged to keep Personal Data for a longer period in compliance with an obligation to
law or by order of an authority.
At the end of the retention period, Personal Data will be deleted. Therefore, at the expiration of
this term the right of access, cancellation, rectification and the right to data portability
they can no longer be exercised.
The use of the data collected
User data are collected to allow the owner to provide their services, as well as for
following purposes: Statistics, Interaction with external social networks and platforms, Access to
account on third party services and Contact the User.
To obtain further detailed information on the purposes of the processing and on Personal Data
concretely relevant for each purpose, the User can refer to the relevant sections of
Facebook permissions requested by la farmaveloce.com
Unless otherwise specified
The site may request some Facebook permissions that allow it to perform actions with the account
User's Facebook and to collect information, including Personal Data, from it. This service
allows the site to connect with the User's account on the Facebook social network, provided by
For more information on the following permissions, refer to the documentation of the
The required permits are as follows:
The basic information of the User registered on Facebook which normally includes the following
Data: id, name, image, gender and localization language and, in some cases, the "Friends" of
Facebook. If the User has made publicly available additional data, the same will be available.
Access to private data
Allows access to the User's and friends' private data.
Access to friend lists
Provides access to the lists of friends that the User has created.
Add or edit photos.
Allows the app to add or edit User videos.
Provides access to the list of events in which the User participates.
I like it
Provides access to the list of all the pages that the User has marked with the Like.
Provides access to the User's website.
Details on the processing of Personal Data
The Personal Data are collected for the following purposes and using the following services:
Access to accounts on third party services
This type of service allows the site to collect data from your accounts on third party services and
perform actions with them.
These services are not activated automatically, but require express authorization
Access to the Facebook account (farmaveloce.com)
This service allows the site to connect with the User's account on the social network
Facebook, provided by Facebook, Inc.
Permissions asked: Access to private data, Access to friend lists, Upload photos, Upload of
Videos, Events, Likes and Website.
Contact the user
By filling in the contact form with their Data, the User consents to their use for
respond to requests for information, quotes, or any other kind indicated
from the form header.
Personal data collected: post code, city, tax code, surname, address, country, name, number of
telephone, VAT number and various types of data.
Interaction with external social networks and platforms
This type of service allows you to interact with social networks, or with other platforms
external, directly from the pages of the site
The interactions and information acquired from the site are in any case subject to the settings
User privacy related to each social network.
In the event that an interaction service with social networks is installed, it is possible that, too
if Users do not use the service, it collects traffic data relating to the pages in
which it is installed on.
Like button and social widgets for Facebook (Facebook, Inc.)
The "Like" button and Facebook social widgets are social interaction services
Facebook network, provided by Facebook, Inc.
Personal Data collected: Cookies and Usage Data.
The services contained in this section allow the Data Controller to monitor and
analyze traffic data and are used to keep track of User behavior.
Google Analytics (Google Inc.)
Google Analytics is a web analysis service provided by Google Inc. ("Google"). Google uses i
Personal data collected for the purpose of tracking and examining the use of farmaveloce.com,
compile reports and share them with other services developed by Google.
Google may use the Personal Data to contextualise and personalize the advertisements of the
own advertising network.
Personal Data collected: Cookies and Usage Data.
More information on Personal Data
Selling goods and services online
The Personal Data collected is used for the provision of services to the User or for the sale of
products, including payment and possible delivery. Personal Data collected to perfect the
payment may be those relating to the credit card, the current account used for the
bank transfer or other expected payment instruments. Payment data collected by
farmaveloce.com depend on the payment system used.
Users may exercise certain rights with reference to the Data processed by the Data Controller.
In particular, the User has the right to:
• withdraw consent at any time. The User can withdraw consent to the treatment
of their Personal Data previously expressed.
• object to the processing of their data. The user can object to the processing of their data
when it occurs on a legal basis other than consent. Further details on the law
of opposition are indicated in the section below.
• access their Data. The User has the right to obtain information on the Data processed by the
Holder, on certain aspects of the treatment and to receive a copy of the Data processed.
• verify and request correction. The User can verify the correctness of their Data
and request its updating or correction.
• obtain the limitation of the treatment. When certain conditions are met,
the User can request the limitation of the processing of their Data. In this case the Owner
will not process the Data for any other purpose other than their conservation.
• obtain the cancellation or removal of their Personal Data. When they recur
certain conditions, the User can request the deletion of their Data by the
• receive your data or have it transferred to another holder. The User has the right to receive i
own Data in structured format, commonly used and readable by automatic device and, where
technically feasible, to obtain the transfer without hindrance to another owner. This
provision is applicable when the Data are processed with automated tools and the
processing is based on the User's consent, on a contract of which the User is a party or on
contractual measures connected to it.
• propose a complaint. The User can lodge a complaint with the supervisory authority of the
protection of personal data competent or to act in court.
Details on the right of opposition
When Personal Data are processed in the public interest, in the exercise of public powers referred to
the Owner is invested or to pursue a legitimate interest of the Owner, the Users have
right to object to processing for reasons related to their particular situation.
Users are reminded that if their data were processed for direct marketing purposes,
can oppose the treatment without giving any reason. To find out if the owner deals
data for direct marketing purposes Users can refer to the respective sections of
How to exercise the rights
To exercise the User's rights, Users can address a request to the ends of
contact of the Owner indicated in this document. Requests are filed free of charge and
processed by the Owner as soon as possible, in any case within a month.
Additional information on treatment
Defense in court
The User's Personal Data may be used by the Owner in court or in stages
preparatory to its possible establishment for the defense against abuse in the use of
farmaveloce.com or related Services by the User.
The User declares to be aware that the Data Controller may be obliged to reveal the Data
by order of the public authorities.
farmaveloce.com could provide the User with additional and contextual information
concerning specific Services, or the collection and processing of Personal Data.
Log System and Maintenance
For needs related to the operation and maintenance of the site and any third party services from
it used could collect system logs, that is files that record the interactions and that
they may also contain Personal Data, such as the User IP address.
Information not contained in this Policy
Further information in relation to the processing of Personal Data may be requested in
at any time to the Data Controller using the contact details.
Response to "Do Not Track" requests
The site does not support "Do Not Track" requests.
To find out if any third-party services used support them, the User is invited to
consult the respective privacy policies.
any time giving information to Users on this page and, if possible, on the site
as well as, if technically and legally feasible, by sending a notification to Users through one
of the contact details held by the Owner. Therefore, please consult regularly
this page, referring to the date of last modification indicated at the bottom.
If the changes affect treatments whose legal basis is consent, the Owner
will collect the User's consent again, if necessary.
Definitions and legal references
Personal Data (or Data)
It constitutes personal data any information that, directly or indirectly, also in
link with any other information, including an identification number
personal, makes a natural person identified or identifiable.
Data of Use
This is the information collected automatically through the site (also by party applications
third parties integrated into the site), including: IP addresses or domain names of the computers used
by the User who connects with the site, the addresses in URI (Uniform Resource Identifier) notation,
the time of the request, the method used to forward the request to the server, the file size
obtained in response, the numeric code indicating the status of the response from the server (successful, error,
etc.) the country of origin, the characteristics of the browser and operating system used by the
visitor, the various temporal connotations of the visit (for example the time spent on
each page) and the details of the itinerary followed within the Application, with
particular reference to the sequence of the pages consulted, to the parameters relating to the system
operating environment and the IT environment of the User.
The individual who uses the site which, unless otherwise specified, coincides with the interested party.
The natural person to whom the Personal Data refers.
Data Processor (or Manager)
The natural person, legal entity, public administration and any other entity that processes data
Data Controller (or Owner)
The natural or legal person, public authority, service or other body which, individually or
together with others, it determines the purposes and means of the processing of personal data and the tools
adopted, including the security measures relating to the operation and use of
farmaveloce.com. Unless otherwise specified, the Data Controller is the
owner of farmaveloce.com.
farmaveloce.com (or this Application)
The hardware or software tool through which the Personal Data of the
The service provided by the site as defined in the relative terms (if any) on this
site / application.
European Union (or EU)
Unless otherwise specified, any reference to the European Union contained in this
document is intended to be extended to all current member states of the European Union and Space
Small portion of data stored in the User's device.
This privacy statement is drawn up on the basis of multiple legislative systems, including articles 13 and 14 of the Regulation (EU) 2016 / 679.
Unless otherwise specified, this privacy statement only concerns the site.
RIGHT OF WITHDRAWAL
Deadline for withdrawal
The Consumer has a period of fourteen days to withdraw from the contract without having to provide any reason.
The aforementioned term starts:
a) if a service is offered from the day of the conclusion of the contract
b) in the case of sale of a product, from the day on which the Consumer or a third party, other than the carrier and designated by the Consumer, acquires physical possession of the goods or:
• in the case of multiple goods ordered by the Consumer through a single order and delivered separately, from the day on which the Consumer or a third party, other than the carrier and designated by the Consumer, acquires physical possession of the last good;
• in the case of delivery of an asset consisting of lots or multiple pieces, from the day on which the Consumer or a third party, other than the carrier and designated by the Consumer, acquires physical possession of the last lot or piece;
• in the case of contracts for the periodic delivery of goods during a certain period of time, from the day on which the Consumer or a third party, other than the carrier and designated by the Consumer, acquires physical possession of the first asset.
Obligations of the pharmacy The pharmacy, following the withdrawal of the consumer:
• immediately communicates to the Consumer a confirmation of receipt, on a durable medium, of the Withdrawal exercised;
• reimburses the same all payments received, not including delivery costs, without undue delay and in any case within fourteen days from the day of the communication of the Right of Withdrawal.
• the pharmacy reimburses using the same means of payment used by the Consumer, unless otherwise agreed after payment.
Obligations for the Consumer
The shipping costs for the return of the products received must be paid by the Consumer, which must be shipped within fourteen days from the date on which he communicated his decision to withdraw from the contract (the deadline is respected if the Consumer returns the goods before the expiry of the fourteen day period).
The substantial integrity of the asset is an essential condition for exercising the right of withdrawal. The Product must therefore be kept with normal diligence and returned intact, complete in all its parts, fully functional and free of signs of wear or dirt.
Exceptions to the Right of Withdrawal - products for which the application of the Right of Withdrawal is excluded
The right of withdrawal cannot be exercised:
a) in case of purchase of medicines and medical devices
b) supply of food, drinks or other goods intended for current consumption in the family and physically supplied by a professional in frequent and regular rounds to the consumer's home, residence or workplace
c) in the case of purchases of less than 50 euros (unless the total consideration that the Consumer must pay regardless of the amount of the individual contracts exceeds 50 euros);
d) in the case of a contract for a service after the complete provision of the service if the execution of the contract began with the express agreement of the Consumer;
e) in case of supply of goods made to measure or clearly personalized;
f) in the event of the supply of goods which are liable to deteriorate or expire rapidly;
g) in the case of the supply of sealed goods that do not lend themselves to be returned for reasons of hygiene or connected to the protection of health and have been opened after delivery;
h) in case of supply of goods which after delivery are by their nature inseparably mixed with other ben.
In the event of a lack of conformity, or delivery of goods that present defects or defects or are different from that provided in the sales contract, i.e. unsuitable for the use for which a good of the same is usually used
type, which differs from the description published on the site or which does not manifest the promised qualities, the provisions of the Legal Guarantee as per articles 128 and following of Legislative Decree 205/2006 (Consumer Code).
Any breakdowns or malfunctions caused by accidental events or by Customer's liability or by a use of the product not in accordance with its intended use and / or as foreseen in the technical documentation attached to the product are excluded from the scope of the Legal Guarantee.
The pharmacy is liable when the lack of conformity occurs within two years from the delivery of the goods, unless there is a conventional guarantee beyond this term. In case of sale of used goods, the guarantee referred to in the previous paragraph may be limited to a period of time however
not less than one year.
The Consumer is required to report the defect or defect to me quickly within two months of discovery (unless the sector has recognized or concealed the existence of the defect).
It is assumed that the defects of conformity that occur within six months of delivery of the goods already existed on that date, unless this hypothesis is incompatible with the nature of the asset or with the nature of the defect of
The direct action to assert defects not maliciously concealed by the seller is prescribed within twenty-six months from the delivery of the goods (the Consumer who is agreed for the execution of the contract can nevertheless always assert the rights referred to in this article provided that the lack of conformity has been reported within two months of discovery and before the expiry of the two years from delivery).
In the event of a lack of conformity, the Consumer can request, at no cost (including shipping), the restoration by repair or replacement, at his choice, unless the remedy is objectively impossible or excessively expensive compared to the other.
The above remedy is to be considered excessively expensive if it imposes unreasonable costs on the store compared to the other, taking into account:
a) the value that the asset would have if there were no lack of conformity;
b) the extent of the lack of conformity;
c) the possibility that the alternative remedy can be tried without significant inconvenience for the Consumer.
Repairs or replacements will be carried out within a reasonable time from the request and must not cause significant inconvenience to the Consumer, taking into account the nature of the goods and the purpose for which it was purchased.
The Consumer can request, at his choice, a reasonable reduction in the price or termination of the contract if one of the following situations occurs:
a) repair and replacement are impossible or excessively expensive;
b) the seller did not replace within a reasonable time;
c) the replacement or repair previously carried out has caused significant inconvenience to the Consumer.
The use of the asset is taken into account when determining the amount of the reduction or the amount to be returned.
After reporting the lack of conformity, the seller can offer the consumer any other available remedy, with the following effects:
a) if the Consumer has already requested a specific remedy, the seller remains obliged to implement it, with the necessary consequences regarding the commencement of the appropriate term for repairs or replacements, unless the Consumer accepts the proposed alternative remedy;
b) if the Consumer has not already requested a specific remedy, the Consumer must accept the proposal or reject it by choosing another remedy pursuant to this article.
A slight lack of conformity, for which it has not been possible or is excessively burdensome to carry out the remedies of repair or replacement, does not give the right to terminate the contract.
The Legal Guarantee is limited to purchases made by Consumers. As regards subjects other than Consumers, the provisions of the Consumer Code apply to Articles 1490 et seq.
Conventional Manufacturer Warranty
The products sold on the Site may, depending on their nature, be covered by a conventional warranty issued by the manufacturer ("Conventional Warranty"). The customer can only enforce this guarantee against the manufacturer. The duration, the extension, also territorial, the conditions and methods of use, the types of damage / defects covered and any limitations of the Conventional Warranty depend on the individual manufacturer and are indicated in the so-called warranty certificate contained in the product packaging. The Conventional Guarantee is voluntary in nature and does not add, replace, limit or prejudice or exclude the Legal Guarantee.
Payment and security
Your payment information is processed securely. We do not store credit card details nor do we have access to your credit card information.
Lactoferrin 200 Mg Immuno 30 Stickpack
LATTOFERRINA 200 IMMUNO is a food supplement of lactoferrin. Lactoferrin is a multifunctional protein with antimicrobial and antiviral properties